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Open aSummary
Objective: To evaluate the efficacy and tolerability of the selective CRTh2 (DP2) receptor
antagonist AZD1981 compared with placebo in patients with moderate to severe COPD.
Methods: In this multicentre, randomised, double-blind, parallel-group, phase IIa study
(ClinicalTrials.gov identifier: NCT00690482) patients with moderate to severe COPD received
either AZD1981 1000 mg twice daily or matching placebo for 4 weeks. Inhaled terbutaline
was used as-needed as reliever medication throughout. The co-primary endpoints were change
from baseline to end of treatment in pre-bronchodilator forced expiratory volume in 1 s [FEV1]
and the Clinical COPD Questionnaire (CCQ). Additional endpoints included other lung function
measures, 6-min walk test (6-MWT), COPD symptom score, reliever medication use and toler-
ability.
Results: 118 patients were randomised to treatment (AZD1981 nZ 61; placebo nZ 57); 83% of
patients were male and the mean age was 63 years (range 43e83). There were no significant
differences in the mean difference in change from baseline to end of treatment between
AZD1981 and placebo for the co-primary endpoints of pre-bronchodilator FEV1 (AZD1981
eplacebo: 0.015, 95% CI: 0.10 to 0.070; p Z 0.72) and CCQ total score (difference:
0.042, 95% CI: 0.21 to 0.30; p Z 0.75). Similarly, no differences were observed between
treatments for the other outcomes of lung function, COPD symptom score, 6-MWT, BODE index,
and use of reliever medication. AZD1981 was well tolerated.Infection Firm, The Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK. Tel.: þ44 (0) 1491
s.uk, n.snell@doctors.org.uk (N. Snell).
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CRTh2 antagonist AZD1981 in moderate to severe COPD 1723Conclusion: There was no beneficial clinical effect of AZD1981, at a dose of 1000 mg twice
daily for 4 weeks, in patients with moderate to severe COPD. AZD1981 was well tolerated
and no safety concerns were identified.
ª 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Chronic obstructive pulmonary disease (COPD) is an in-
flammatory lung disease characterised by airflow limitation
that is not fully reversible, and often excessive mucus
production and cough [1]. The airflow limitation charac-
teristic of COPD is associated with an exaggerated inflam-
matory response of the lungs to noxious particles or gases
including tobacco smoke [2,3]; the resulting damage in-
cludes disruption of the mucosal barrier and increased
bronchiolitis and vasculitis.
Current first-line pharmacological therapies for COPD
focus on the use of bronchodilators, with added inhaled
corticosteroids in patients at risk of exacerbations. The oral
phosphodiesterase IV (PDE4) inhibitor, roflumilast, can be
used in patients with severe airflow limitation, frequent
exacerbations and chronic bronchitis further to reduce the
risk of exacerbations. These treatments provide some
symptomatic relief but there are no current marketed
therapies that have been shown to alter mucosal integrity,
vascular or parenchymal changes or to alter inflammatory
status in COPD patients. As such, there is no therapy
available apart from smoking cessation that consistently
modulates disease progression.
The chemoattractant receptor-homologous molecule
expressed on Th2 cells (CRTh2) receptor (previously known
as DP2) is highly expressed on human Th2 cells (but not Th1
cells), eosinophils, basophils and a subset of monocytes
[4e6]; blocking the endogenous ligand (prostaglandin D2) at
this receptor inhibits chemotaxis in these cells [7]. Hence
the CRTh2 receptor is a potential therapeutic target in
allergic disorders of the respiratory tract. Several CRTh2
antagonists have progressed into clinical studies [8e10] and
preliminary reports describe positive effects on reducing
allergen-induced eosinophil count and circulating IgE levels
in asthmatic patients [11].
Preclinical data have also shown that CRTh2 antagonism
inhibited tobacco-smoke-induced inflammation and mucosal
damage including mucus cell metaplasia and epithelial hy-
perplasia in a mouse model of inflammation [12,13]. CRTh2
receptor expression has been observed in COPD lung tissue,
on mononuclear infiltrates and respiratory mucosal epithe-
lial cells (see Methods and Results sections). Hence, inhibi-
tion of the CRTh2 receptor could also provide therapeutic
benefits to patients with COPD via a new mechanism; the
theoretical basis for this has been argued by Stebbins et al.
[14]. Indeed, the dual thromboxane and CRTh2 receptor
antagonist seratrodast has been reported to improve lung
function in an 8-week study in a cohort of patients with
chronic pulmonary emphysema [15].
AZD1981 is an oral, non-steroidal, CRTh2 receptor
antagonist [16,17] that was well-tolerated in phase I trials
and has been studied in asthma patients [18]. The aim of
this phase IIa study was to evaluate the efficacy andtolerability of AZD1981 compared with placebo in patients
with moderate to severe COPD.
Methods
Expression of CRTh2 receptor in COPD lung
As a preliminary to the clinical trial, CRTh2 receptor expres-
sion was examined in a range of COPD human lung resections
showing a wide range of cellular pathology changes from
minimal to severe. In brief, immunohistochemistry was
employed on formalin-fixed, paraffin-embedded sections
from tissue obtained from lung volume reduction surgery
(n Z 8) and lobectomy (n Z 4) procedures. A rabbit anti-
human primary antibody (Cambridge Research Bio-
chemicals)wasusedataworkingconcentrationof 0.0108mg/
mL with a biotinylated swine anti-rabbit employed as sec-
ondary. Detection of signal was StepABC Complex/HRP
(DAKO) with DAB chromogenic detection (DAKO).
Clinical trial design
This was a randomised, double-blind, placebo-controlled,
parallel-group, phase IIa, 4-week study (Study code:
D9831C00001; ClinicalTrials.gov identifier: NCT00690482) of
the selective CRTh2 receptor antagonist AZD1981 in pa-
tients with moderate to severe COPD conducted at 22
centres across 5 European countries (Bulgaria, Denmark,
Poland, Slovakia and Sweden).
Eligible patients were enrolled in a 2-week run-in
period. After the run-in period, patients who fulfilled the
randomisation criteria entered the 4-week treatment
period with either AZD1981 1000 mg twice daily or matching
placebo, in a 1:1 ratio.
This study was performed in accordance with the ethical
principles that have their origin in the Declaration of Hel-
sinki and that are consistent with International Conference
on Harmonisation/Good Clinical Practice and applicable
regulatory requirements and the AstraZeneca policy on
Bioethics. Approval was also obtained from the Institutional
Review Boards/Independent Ethics Committees in the
respective countries.
Patients
Male and female patients 40 years of age with a clinical
diagnosis of moderate to severe COPD (GOLD stages II and
III) [1]; post-bronchodilator FEV1 of 30e80% of predicted
normal, and post-bronchodilator FEV1/forced vital capacity
(FVC) <70%, symptoms for >12 months, current or ex-
smokers with a smoking history of at least 10 pack-years,
and use of inhaled short-acting b2-agonists and/or anti-
cholinergics as reliever during 1 year prior to the start of
1724 N. Snell et al.the study were eligible for inclusion. Female patients had
to be of non-childbearing potential.
For randomisation in the study at Visit 2 the patients also
had to fulfil the following criteria: a score of 1 on the
COPD symptom breathing score (5-point scale ranging from
0 [good] to 4 [bad]) on at least half of the days of the run-in
period and a score of 2 on the COPD symptom sputum
score (same 5-point scale as breathing score) on at least
half of the days of the run-in period.
Patients receiving inhaled corticosteroid (ICS) therapy
and/or stable doses of ipratropium/oxitropium prior to run-
in were allowed to continue their pre-study medication
throughout the study. However, long-acting b2-agonists
(LABAs) and long-acting anti-muscarinic agents (LAMAs) had
to be discontinued prior to inclusion. Patients on combina-
tion ICS/LABA therapy were transferred to the correspond-
ing ICS monotherapy. Inhaled short-acting b2-agonist therapy
(terbutaline) was provided as reliever medication to be used
as-needed throughout the run-in and treatment period.
Treatments
Patients received either AZD1981 1000 mg orally (adminis-
tered as four 250 mg tablets) or matching placebo twice
daily, in the morning and the evening. Patients took the
first dose of study medication at the clinic at baseline (Visit
2; on completion of the 2-week run-in period). Additional
clinic visits took place at weeks 1, 2, 3 and 4 of the treat-
ment period with a follow-up visit one week after the final
on-treatment visit.
Objectives and endpoints
The primary objective of the study was to evaluate the
efficacy of AZD1981 compared with placebo in patients with
moderate to severe COPD; the secondary objective was to
evaluate the tolerability of AZD1981 compared with pla-
cebo in this patient population.
The co-primary study endpoints were change from
baseline to end of treatment in pre-bronchodilator FEV1
and the Clinical COPD Questionnaire (CCQ) [19]. Additional
efficacy endpoints were change from baseline to end of
treatment in the lung function measures FVC, slow vital
capacity (SVC), inspiratory capacity (IC), forced expiratory
flow between 25% and 75% of the FVC (FEF25e75%), the 6-
min walk test (6-MWT), COPD symptom score, morning
and evening peak expiratory flow (PEF), BODE index and
reliever medication use.
Safety was assessed throughout by reporting the nature,
incidence and severity of adverse events (AEs). ECG, pulse,
blood pressure and safety laboratory parameters (clinical
chemistry, haematology and urinalysis) were also recorded
at each clinic visit.
Statistical analysis
A sample size of 100 patients, 50 in each treatment group,
was determined to have 80% power to detect a difference
on FEV1 of 0.125 L between the treatment groups, assuming
a common standard deviation of 0.25 L, using a one-sided
test with a significance level of 0.05.Efficacy data were analysed using an additive analysis of
variance (ANOVA) model, with treatment and country as
factors and baseline measurements as covariate. The
outcome variable for diary card variables was the change
from run-in period average to treatment period average.
For other data the outcome variable was the change from
last pre-dose value to last post-dose value.
All AE data were summarised for each treatment and
analysed by means of descriptive statistics and qualitative
analysis. All hypothesis testing was done using two-sided
alternative hypotheses. p-Values <0.1 were considered
statistically significant on two-sided tests (i.e. <0.05 on
one-sided tests).
Results
Expression of CRTh2 receptor in COPD lung
Expression of the CRTh2 receptor was found on a range of
both inflammatory and resident cell types in all lung spec-
imens (Fig. 1). A prominent expression was seen on multi-
focal inflammatory infiltrates (notably mononuclear cell
infiltrates) and on lymphoid tissue cells as well as on cells
embedded within mucus plugs in the central airways.
CRTh2 expression was noted on mononuclear cells both
within the lung tissue and on cells adhering to the endo-
thelial surface and trafficking through the vessel walls of
the pulmonary vasculature.
An interesting, and consistent, finding was the obser-
vation of CRTh2 expression on mucosal epithelial cells.
There was a range of epithelial phenotypes noted in this
sample set e hypertrophic, hyperplasic, metaplastic and
examples of both basal cell and squamous cell metaplasia.
Not all cells of similar morphology expressed CRTh2 e there
were many examples of cells showing marked expression
adjacent to cells which showed little or no expression.
CRTh2 expression was marked on hypertrophic and hyper-
plastic epithelium but was less intense, with a more diffuse
pattern, on metaplastic cell types. With regards to the
hypertrophic and hyperplastic phenotypes, expression of
CRTh2 was markedly focal e showing a dense expression
pattern at the apical surface of the epithelium. This
pattern was less marked on the metaplastic forms, which
may reflect either changes in receptor density on the cells
or changes in cell morphology and volume as the epithelial
cells move through the differentiation sequence.
Clinical trial findings
A total of 156 patients were enrolled in the study, of whom
118 were considered eligible for randomisation to treat-
ment (AZD1981 nZ 61; placebo nZ 57). Of the 7 patients
who discontinued during the study (AZD1981 nZ 4; placebo
n Z 3), 3 were withdrawn because of adverse events, one
because of incorrect enrolment, one because of non-
allowed concomitant medication, one because of
elevated liver enzyme levels and one withdrew consent
(randomised to placebo) immediately after receiving the
first dose (Fig. 2); since no data were collected on this
patient, the patient was listed in the category “Not treated
or no data on treatment” and excluded from the placebo
Figure 1 Three typical lung fields (20) showing expression
of CRTh2 receptor in airway mucosa. (A) shows a mainly hy-
perplastic epithelium with prominent Goblet cell hypertrophy.
Note receptor expression on epithelium with denser expression
at the apical surface. (B) shows a metaplastic epithelium with
a squamous phenotype and diffuse CRTh2 expression. Note
positive inflammatory cells within the connective tissue zone
and within the lumen mucus deposit. (C) shows a mixed
phenotype epithelium with intra-epithelial leucocytes. There
is punctate expression of CRTh2 within the epithelium and
connective tissue zone.
CRTh2 antagonist AZD1981 in moderate to severe COPD 1725group dataset. Of the 117 patients allocated to treatment,
97 (83%) were male and 20 (17%) were female; all patients
were Caucasians aged between 43 and 83 years (mean age
63.3 years). The median time since diagnosis of COPD was 6
years and the median number of pack years of smoking was
36. The treatment groups were comparable at baseline with
respect to demographic characteristics except that the
AZD1981 group had a higher mean inhaled corticosteroid
dose at entry and a slightly lower FEV1 (Table 1).Efficacy
AZD1981 at a dose of 1000 mg twice daily for 4 weeks did
not have any effect on the co-primary study endpoints of
change from baseline in pre-bronchodilator FEV1 and CCQ
(total score and individual symptom, function and mental
scores) compared with placebo (Fig. 3A and B). There were
no statistically significant differences in the mean change
from baseline to end of treatment between AZD1981 and
placebo for FEV1 (difference: 0.015, 95% CI: 0.10 to
0.070; p Z 0.72), CCQ total score (difference: 0.042, 95%
CI: 0.21 to 0.30; p Z 0.75), CCQ symptom score (differ-
ence: 0.020, 95% CI: 0.28 to 0.32; pZ 0.90), CCQ function
score (difference: 0.064, 95% CI: 0.22 to 0.35; p Z 0.66)
and CCQ mental score (difference: 0.005, 95% CI: 0.37
to 0.36; p Z 0.98).
Similarly, no differences were observed between treat-
ments on the other clinically measured spirometric vari-
ables of FVC (difference: 0.028, 95% CI: 0.14 to 0.20;
pZ 0.75), SVC (difference: 0.025, 95% CI: 0.21 to 0.16;
p Z 0.79), IC (difference: 0.063, 95% CI: 0.10 to 0.23;
pZ 0.45) and FEF25e75 (difference: 0.12, 95% CI: 0.24 to
0.003; p Z 0.056) (Fig. 4).
Following 4 weeks of treatment, no differences were
observed between treatment arms for PEF, COPD symptom
score, use of reliever medication, 6-MWT and BODE score
after 4 weeks of treatment (Table 2).Tolerability
A total of 20 patients (33%) in the AZD1981 group experi-
enced an AE compared with 18 patients (32%) in the pla-
cebo group. The majority of adverse events were mild in
intensity and no AEs of severe intensity were reported. The
most frequently reported adverse events were nasophar-
yngitis (in total: 9 patients [8%]) and COPD (8 patients [7%]);
twice as many patients in the AZD1981 group reported
nasopharyngitis as those receiving placebo (Table 3).
One patient (receiving placebo) experienced a serious
AE of COPD exacerbation resulting in hospitalisation. There
were 4 discontinuations due to AEs during the treatment
period: 3 of these were in patients receiving AZD1981 (2
cases of a COPD exacerbation and 1 elevation of liver en-
zymes) and 1 was a patient receiving placebo (a COPD
exacerbation). There were no deaths during the study.
There were no marked changes in haematology, clinical
chemistry and urinalysis parameters. There were no clini-
cally relevant differences between the treatment groups in
safety laboratory variables, ECG, vital signs or physical
examination.
Figure 2 Patient flow through the study.
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This study was the first to examine the expression of CRTh2
receptors in COPD lung, and the pulmonary effects of the
oral CRTh2 antagonist AZD1981 in patients with COPD. The
primary objective of the study was to explore the efficacy
of 4 weeks’ treatment with AZD1981 in patients with COPD
and the secondary objectives were to assess its safety and
tolerability. There was no indication of a beneficial clinicalTable 1 Patients’ baseline demographics and disease characte
Characteristic
Gender, n (%)
Male
Female
Mean age, years (range)
Mean body mass index, kg/m2 (range)
Smoking status, n (%)
Previous
Occasional
Habitual
Mean pack-years (range)
ICS at entry, n (%)
Yes
No
Mean daily dose, mg (range)
Lung function parameters (mean)
FEV1 post-bronchodilator, L (range)
FEV1 pre-bronchodilator, L (range)
FEV1, post-bronchodilator, % predicted normal (range)
FVC, L (range)
FEV1/FVC ratio, % (range)
Mean no. of reliever inhalations/day, n (range)
Abbreviations: FEV1, forced expiratory volume in 1 min; FVC, forcedeffect of AZD1981 in patients with moderate to severe
COPD given at a dose of 1000 mg twice daily for 4 weeks.
The rationale for testing the CRTh2 antagonist AZD1981
on patients with COPD stems from preclinical data showing
that the CRTh2 antagonist inhibited tobacco-smoke-
induced inflammation and mucosal damage, including
mucus cell metaplasia and epithelial hyperplasia, in a
mouse model [12,13]. This, combined with the finding of
CRTh2 receptor expression in COPD lung tissue, onristics (n Z 117).
AZD1981 (n Z 61) Placebo (n Z 56)
49 (80) 48 (86)
12 (20) 8 (14)
64.1 (47e78) 62.4 (43e83)
24.8 (18e31) 24.9 (17e30)
27 (44) 27 (48)
2 (3) 2 (4)
32 (52) 27 (48)
35 (12e99) 36 (10e81)
47 (77) 38 (68)
14 (23) 18 (32)
680.4 (320e1600) 545.3 (200e1600)
1.55 (0.7e2.7) 1.66 (0.8e2.8)
1.42 (0.5e2.7) 1.58 (0.7e2.7)
53.1 (31e79) 55.3 (31e100)
3.08 (1.3e6.5) 3.11 (1.8e4.9)
50.9 (34e70) 53.4 (31e70)
3.6 (0e12) 3.1 (0e9)
vital capacity; ICS, inhaled corticosteroid.
CRTh2 antagonist AZD1981 in moderate to severe COPD 1727mononuclear infiltrates and mucosal epithelial cells and the
fact that the dual thromboxane and CRTh2 receptor
antagonist seratrodast improved lung function in an 8-week
study in patients with chronic pulmonary emphysema [15]
suggested that inhibition of CRTh2 receptors might pro-
vide therapeutic benefits to patients with COPD.
There are a number of possible reasons for the negative
finding in this study. There are differences in CRTh21.65
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Figure 3 (A) Pre-bronchodilator FEV1 and change from baseline p
CCQ in patients with moderate to severe COPD receiving either AZDexpression patterns between mouse and human so mouse
models may not be wholly predictive of effects in man [14].
The time course for any clinical effect of a CRTh2 antago-
nist in patients with COPD is far from clear. It is equally
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AZD1981 at a dose of 1000 mg twice daily or placebo for 4 weeks.
1728 N. Snell et al.studies of longer duration had not been reported. The study
was, therefore, designed both as a signal searching study,
to find out if any clinical effects of AZD1981 in COPD pa-
tients can be detected after only 4 weeks of treatment, and
as a safety and tolerability study, to facilitate the step fromTable 2 Treatment effect of AZD1981 on lung function and othe
(change from baseline to last assessment).
Variable Estimated
mean differencea
COPD symptomsb
Breathing 0.082
Cough 0.111
Sputum 0.003
Sleeping 0.067
Use of reliever medication
Total daily reliever use 0.048
Day-time reliever use 0.024
Night-time reliever use 0.073
6-min walk test, m 2.7
BODE index score 0.11
PEF, L/min
Morning 2.76
Evening 8.47
Abbreviation: PEF, peak expiratory flow.
a ANOVA estimated difference AZD1981 versus placebo (original val
b Symptoms rated on a 5-point scale (0: good through to 4: bad).short-term healthy volunteer studies to longer studies in
COPD patients from a safety and tolerability perspective. In
terms of efficacy, two co-primary efficacy endpoints were
chosen, FEV1 as measure of lung function and CCQ as
measure of health status, in order to provide a level ofr outcome measures in patients with moderate to severe COPD
95% confidence interval p-Value (treatment effect)
0.239 to 0.075 0.305
0.286 to 0.063 0.208
0.176 to 0.181 0.974
0.232 to 0.099 0.427
0.695 to 0.599 0.883
0.401 to 0.448 0.651
0.394 to 0.247 0.912
20 to 15 0.76
0.28 to 0.50 0.57
10.1 to 4.61 0.460
16.3 to 0.585 0.035
ues).
Table 3 The most frequently reported adverse events
(reported in at least 3% of patients).
Adverse event, n (%) AZD1981
(n Z 61)
Placebo
(n Z 56)
Nasopharyngitis 6 (10) 3 (5)
COPD 4 (7) 4 (7)
Urinary
tract infection
1 (2) 2 (4)
Cough 2 (3) 1 (2)
CRTh2 antagonist AZD1981 in moderate to severe COPD 1729confidence when interpreting the study. Also, since the
mode of action of a CRTh2 antagonist in COPD is different
from those of current COPD therapies, the study was
designed to address the effect of AZD1981 with a variety of
background medication. Enrolled patients who were on ICS
and/or ipratropium/oxitropium maintenance therapy were
allowed to continue on their pre-study regimen throughout
the study while LAMAs and LABAs were discontinued and
patients using an ICS/LABA combination inhaler were
transferred to the corresponding ICS monotherapy. Overall,
this resulted in about 70% of patients in the study receiving
ICS and 40% were receiving anticholinergics, and while the
discontinuation of LAMAs and LABAs was intended to allow
improvement in lung function to be detected, this high
level of maintenance therapy may have diminished the
ability to detect an independent effect from AZD1981.
In a separate phase II study evaluating histological and
cellularity effects of AZD1981 given for 4 weeks in patients
with COPD, AZD1981 reduced the percentage of eosinophils
in induced sputum compared with placebo; however, no
evidence of clinical efficacy of AZD1981 over the 4-week
treatment period was observed and effects on airway his-
tology were not seen [20]. The reduction in the percentage
of eosinophils in induced sputum is consistent with the
mechanism of action of this drug class and has been seen
with another CRTh2 antagonist in preventing allergen-
induced eosinophilic inflammation in patients with mild
asthma [11]. Whether AZD1981 would have an effect on
eosinophilic inflammation and potentially in preventing
eosinophilic-driven COPD exacerbations remains to be
determined.
The study did not indicate any tolerability or safety is-
sues with AZD1981 that would cause concern for longer-
term studies. In terms of safety, there were no serious AEs
with AZD1981 and nothing noteworthy in the pattern or the
frequency of AEs.
In conclusion, while the results of this 4-week study did
not demonstrate a beneficial clinical effect for AZD1981
1000 mg twice daily, longer-term studies might reveal
benefits in terms of COPD exacerbations in certain patients,
or in slowing the rate of decline in lung function. AZD1981
was well tolerated and no safety concerns were identified.
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